The magic of small-moleculedrugs during ex vivo expansionin adoptive cell therapy
Targeting vasoactive intestinal peptidemediated signaling enhances response toimmune checkpoint therapy in pancreaticductal adenocarcinoma
Comparing VIP and PD-L1 expression as cancer biomarkers
Absence of Vasoactive Intestinal Peptide Expression in Hematopoietic Cells EnhancesAbsence of Vasoactive Intestinal Peptide Th1 Polarization and Antiviral Immunity in Mice
Administration of a vasoactive intestinal peptide antagonist enhances the autologousanti-leukemia T cell response in murine models of acute leukemia
Modulation of Immune Checkpoints andGraft-versus-Leukemia in AllogeneicTransplants by Antagonizing VasoactiveIntestinal Peptide Signaling
VIPhyb, an Antagonist of Vasoactive Intestinal PeptideReceptor, Enhances Cellular Antiviral Immunity in MurineCytomegalovirus Infected Mice
Pharmacological inhibition of VIP signaling enhances antiviral immunityand improves survival in murine cytomegalovirus-infected allogeneicbone marrow transplant recipients
